# A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

> **NCT02291614** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 45 (actual)

## Conditions studied

- GI Adenocarcinoma

## Interventions

- **DRUG:** AMG 211

## Key facts

- **NCT ID:** NCT02291614
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-27
- **Primary completion:** 2017-11-06
- **Final completion:** 2018-01-09
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** The study was terminated because of immunogenicity and business decision.
- **Last updated:** 2021-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02291614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02291614, "A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02291614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*